open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15
Get Citation

Problems in diagnostics of primary aldosteronism - analysis of the own data

Janusz Myśliwiec, Łukasz Żukowski, Anna Grodzka, Agata Piłaszewicz, Szymon Drągowski, Beata Piekut, Agnieszka Nikołajuk, Maria Górska
Endokrynologia Polska 2010;61(1):2-5.

open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15

Abstract


Introduction: During the last few years, increasing evidence suggests that primary aldosteronism is the cause of over 10% of arterial hypertension (AH). There are no "gold standard" methods for PA screening. The aim of study was plasma renin activity (PRA), plasma aldosterone concentration (PAC), and ARR assessment as criteria for diagnosis of PA and their usefulness in clinical practice.
Material and methods: Eighty-one consecutive patients were admitted for diagnosis of primary aldosteronism: 51 women and 30 men, aged 31-69 years. In each patient, PAC and PRA were evaluated by radioimmunoassay. In 65 patients, urine concentration of catecholamine metabolites was assayed, and in 51 patients, diagnostics for hypercortisolaemia was carried out. In patients with adrenal incidentaloma, 16-row computer tomography was performed.
Results: The proportion of patients with PAC over 150 pg/ml was 35% (n = 28). The number of patients with PRA under 0.07 ng/ml/h was 19 (n = 15). The ratio of patients whose values of ARR exceeded over 20, 30, 40, 50, and 180 were 55, 47, 37, 28, and 15%, respectively.
Conclusions: The most common indication for primary screening was the presence of incidentally found adrenal mass. The quotient of plasma aldosterone concentration/plasma renin activity at whichever cut-off point is not effective enough for the selection of patients for further diagnostics or its cessation.
(Pol J Endocrinol 2010; 61 (1): 2-5)

Abstract


Introduction: During the last few years, increasing evidence suggests that primary aldosteronism is the cause of over 10% of arterial hypertension (AH). There are no "gold standard" methods for PA screening. The aim of study was plasma renin activity (PRA), plasma aldosterone concentration (PAC), and ARR assessment as criteria for diagnosis of PA and their usefulness in clinical practice.
Material and methods: Eighty-one consecutive patients were admitted for diagnosis of primary aldosteronism: 51 women and 30 men, aged 31-69 years. In each patient, PAC and PRA were evaluated by radioimmunoassay. In 65 patients, urine concentration of catecholamine metabolites was assayed, and in 51 patients, diagnostics for hypercortisolaemia was carried out. In patients with adrenal incidentaloma, 16-row computer tomography was performed.
Results: The proportion of patients with PAC over 150 pg/ml was 35% (n = 28). The number of patients with PRA under 0.07 ng/ml/h was 19 (n = 15). The ratio of patients whose values of ARR exceeded over 20, 30, 40, 50, and 180 were 55, 47, 37, 28, and 15%, respectively.
Conclusions: The most common indication for primary screening was the presence of incidentally found adrenal mass. The quotient of plasma aldosterone concentration/plasma renin activity at whichever cut-off point is not effective enough for the selection of patients for further diagnostics or its cessation.
(Pol J Endocrinol 2010; 61 (1): 2-5)
Get Citation

Keywords

aldosterone; renin; hypertension; primary aldosteronism

About this article
Title

Problems in diagnostics of primary aldosteronism - analysis of the own data

Journal

Endokrynologia Polska

Issue

Vol 61, No 1 (2010)

Pages

2-5

Published online

2010-03-04

Bibliographic record

Endokrynologia Polska 2010;61(1):2-5.

Keywords

aldosterone
renin
hypertension
primary aldosteronism

Authors

Janusz Myśliwiec
Łukasz Żukowski
Anna Grodzka
Agata Piłaszewicz
Szymon Drągowski
Beata Piekut
Agnieszka Nikołajuk
Maria Górska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl